

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT3127122

|   |   |
|---|---|
| <b>SUBMISSION TYPE:</b>   | NEW ASSIGNMENT                          |
| <b>NATURE OF CONVEYANCE:</b>  | ASSIGNMENT                              |
| <b>CONVEYING PARTY DATA</b>   |   |
| <b>Name</b>   | <b>Execution Date</b>                   |
| JANSSEN PHARMACEUTICA NV  | 05/30/2012                              |
| <b>RECEIVING PARTY DATA</b>   |   |
| <b>Name:</b>  | ASTEX THERAPEUTICS LIMITED              |
| <b>Street Address:</b>  | 436 CAMBRIDGE SCIENCE PARK, MILTON ROAD |
| <b>City:</b>  | CAMBRIDGE                               |
| <b>State/Country:</b>   | UNITED KINGDOM                          |
| <b>Postal Code:</b>   | CB4 0QA                                 |
| <b>PROPERTY NUMBERS Total: 1</b>  |   |
| <b>Property Type</b>  | <b>Number</b>                           |
| Application Number:   | 14404175                                |
| <b>CORRESPONDENCE DATA</b>  |   |
| <b>Fax Number:</b>  | (518)452-5579                           |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> |   |
| <b>Phone:</b>   | (518)452-5600                           |
| <b>Email:</b>   | jdp@hrfmlaw.com                         |
| <b>Correspondent Name:</b>  | ERICA M. HINES                          |
| <b>Address Line 1:</b>  | 5 COLUMBIA CIRCLE                       |
| <b>Address Line 2:</b>  | HESLIN ROTHENBERG FARLEY & MESITI P.C.  |
| <b>Address Line 4:</b>  | ALBANY, NEW YORK 12203                  |
| <b>ATTORNEY DOCKET NUMBER:</b>  | 3084.157A                               |
| <b>NAME OF SUBMITTER:</b>   | ERICA M. HINES                          |
| <b>SIGNATURE:</b>   | /Erica M. Hines/                        |
| <b>DATE SIGNED:</b>   | 12/01/2014                              |
| <b>Total Attachments: 1</b>   |   |
| source=3084157A_JanssenPharmaAstex (H0042133xD16FB)#page1.tif   |   |

**General Assignment**

WHEREAS, Janssen Pharmaceutica NV having its place of business at Turnhoutseweg 30, B-2340 Beerse, Belgium (hereinafter referred to as "Assignor"), is the owner of certain new and useful inventions relating to

**"NEW COMPOUNDS"**

for which on the 30<sup>th</sup> day of May 2012, United Kingdom Patent Application no. 1209613.7 was filed at UK Intellectual Property Office;  
on the 30<sup>th</sup> day of May 2012, USA Patent Application no. 61/653081 was filed at USPTO; and  
on the 14<sup>th</sup> day of March 2013, USA Patent Application no. 61/782233 was filed at USPTO.

WHEREAS, Astex Therapeutics Limited having its place of business at 436 Cambridge Science Park, Milton Road, Cambridge, CB4 0QA, Cambridgeshire, United Kingdom (hereinafter referred to as "Assignee") is desirous of acquiring Assignors' entire right, title and interest therein, including the right to claim priority thereof,


NOW, THEREFORE, BE IT KNOWN, that in view of good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Assignor hereby assigns and transfers, for all countries in the world, to said Assignee its entire right, title and interest, including the right to claim priority, in and to all said inventions disclosed in said applications and in and to said applications, and all foreign equivalents thereof, including all substitutions, divisions, and continuations thereof, and in and to all Letters Patent, that may be granted for said inventions, and in and to all extensions, renewals, and reissues thereof, the same to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment had not been made.

And for purpose of obtaining patent protection in any foreign country, the Assignor hereby agrees that, any right, title and interest, in and to all said inventions disclosed in said applications and in and to said applications, and all foreign equivalents thereof can be directly assigned by the inventors to the Assignee without explicit confirmation of the Assignor.

The Assignor agrees that this general assignment is effective from the 30<sup>th</sup> day of May 2012.


IN TESTIMONY WHEREOF, the Assignor and Assignee set hereunto their hand and seal this date.

For Janssen Pharmaceutica NV



Luc Quaghebeur, Proxy Holder  
Janssen Pharmaceutica NV

For Astex Therapeutics Limited



HARREN JHOTI  
COMPANY DIRECTOR